Sociedad Americana de Hirudoterapia

Destabilase complexes - natural liposome produced by medicinal leeches Hirudo medicinalis

Pharmacology article published in Fundamental & Clinical Pharmacology (1999)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportFarmacología salivalNikonov GI, Titova EA · Fundamental & clinical pharmacology, 1999

Abstract

Electrophoretic analysis of destabilase preparation demonstrates the presence of protein combinations with MW 12.3, 25 and 50 kD. Fraction (MW 12.3 D) is a monomer of destabilase aggregation having properties of micellar proteins and represents a stable lipid-protein complex, where the role of lipid component is played by the stable analogue of prostacyclin (MW 391 D). The synthesis of a low molecular fraction of destabilase is fulfilled with bacteria--symbiont of leeches Aeromonas hydrophila. When the destabilase (MW 12.3 kD) contacts with blood a process of complexe formation is triggered with hirudin and blood plasma kallikrein inhibitor, forming a stable 'destabilase complex' (DC; MW 25 kD), possessing also a high aggregation capacity. Polymer forms of the destabilase complex form a liposome changing its spatial orientation depending on the nature of the solvent. Such structural organization provides a high stability of DC components and a rapid penetration through cellular membranes (transmembrane transfer) and it also provides prophylactic antithrombotic action in the case of peroral application to animals, due to the blockade of vascular platelets (inhibition of platelet aggregation by prostacyclin analogue) and plasmic (inhibition of thrombin activity and blood plasma kallikrein) links of the hemostasis process. Destabilase fraction with MW 50 kD is a dimer of the destabilase complex. As a result of DC destruction (liposome), hirudin, prostacycline analogue and blood plasma kallikrein inhibitor are released.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH terms6-Ketoprostaglandin F1 alphaAeromonas hydrophilaAgedAnimalsAprotininEndopeptidasesHirudinsHumansLeechesLiposomesMicellesMolecular Weight

Resumen

Characterization of destabilase as a natural lipid-protein liposomal complex (12.3, 25, 50 kDa forms) bound to a stable prostacyclin analog, with the low-molecular-weight fraction produced by symbiont Aeromonas hydrophila.

Por qué esto importa para la hirudoterapia

This article describes the structural organization of destabilase complexes from medicinal leeches, reporting that destabilase forms lipid-protein complexes with a prostacyclin analogue (MW 391 D) that self-assemble into liposome-like structures. The abstract states that when destabilase (MW 12.3 kD) contacts blood, it forms a stable complex (MW 25 kD) with hirudin and blood plasma kallikrein inhibitor, providing prophylactic antithrombotic action upon oral application to animals through inhibition of platelet aggregation, thrombin activity, and plasma kallikrein. The authors also report that the low molecular weight destabilase fraction is synthesized by Aeromonas hydrophila, a leech symbiont bacterium. For ASH, this is relevant to understanding the leech secretome and its multifactorial antithrombotic mechanisms. The study is primarily biochemical and structural with referenced animal data, but the abstract provides limited experimental detail and no clinical data, so therapeutic claims should be viewed cautiously.

Citación

Destabilase complexes - natural liposome produced by medicinal leeches Hirudo medicinalis.

Nikonov GI, Titova EA · Fundamental & clinical pharmacology, 1999

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.